Merck Company Stock Fundamentals
| 0QAH Stock | USD 103.50 27.80 21.17% |
Merck Company fundamentals help investors to digest information that contributes to Merck's financial success or failures. It also enables traders to predict the movement of Merck Stock. The fundamental analysis module provides a way to measure Merck's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Merck stock.
At this time, Merck's Tax Provision is quite stable compared to the past year. Interest Income is expected to rise to about 383.2 M this year, although the value of EBIT will most likely fall to about 11.8 B. Merck | Select Account or Indicator |
Merck Company Company Current Valuation Analysis
Merck's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Merck Current Valuation | 279.03 B |
Most of Merck's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Merck Company is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Merck Company has a Current Valuation of 279.03 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The current valuation for all United Kingdom stocks is significantly lower than that of the firm.
Merck Company Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Merck's current stock value. Our valuation model uses many indicators to compare Merck value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Merck competition to find correlations between indicators driving Merck's intrinsic value. More Info.Merck Company is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.67 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Merck Company is roughly 1.49 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Merck's earnings, one of the primary drivers of an investment's value.Merck Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Merck's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Merck could also be used in its relative valuation, which is a method of valuing Merck by comparing valuation metrics of similar companies.Merck is currently under evaluation in current valuation category among its peers.
Merck Fundamentals
| Return On Equity | 0.0761 | ||||
| Return On Asset | 0.0512 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 279.03 B | ||||
| Shares Outstanding | 2.54 B | ||||
| Shares Owned By Insiders | 0.08 % | ||||
| Shares Owned By Institutions | 77.64 % | ||||
| Price To Book | 8.24 X | ||||
| Price To Sales | 4.50 X | ||||
| Revenue | 60.12 B | ||||
| Gross Profit | 42.08 B | ||||
| EBITDA | 12.33 B | ||||
| Net Income | 365 M | ||||
| Cash And Equivalents | 7 B | ||||
| Cash Per Share | 2.76 X | ||||
| Total Debt | 1.37 B | ||||
| Debt To Equity | 1.16 % | ||||
| Book Value Per Share | 15.24 X | ||||
| Cash Flow From Operations | 13.01 B | ||||
| Earnings Per Share | 1.22 X | ||||
| Price To Earnings To Growth | 0.10 X | ||||
| Number Of Employees | 67 K | ||||
| Beta | 0.38 | ||||
| Market Capitalization | 262.63 B | ||||
| Total Asset | 106.67 B | ||||
| Retained Earnings | 53.9 B | ||||
| Working Capital | 6.47 B | ||||
| Annual Yield | 0.03 % | ||||
| Five Year Return | 3.07 % | ||||
| Net Asset | 106.67 B | ||||
| Last Dividend Paid | 2.84 |
About Merck Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Merck Company's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merck using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merck Company based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 60.1 B | 57.6 B | |
| Cost Of Revenue | 16.1 B | 16.7 B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.